NO964200L - Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines - Google Patents

Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines

Info

Publication number
NO964200L
NO964200L NO964200A NO964200A NO964200L NO 964200 L NO964200 L NO 964200L NO 964200 A NO964200 A NO 964200A NO 964200 A NO964200 A NO 964200A NO 964200 L NO964200 L NO 964200L
Authority
NO
Norway
Prior art keywords
treatment
oral tolerance
autoimmune disease
enhancing cytokines
enhancing
Prior art date
Application number
NO964200A
Other languages
Norwegian (no)
Other versions
NO964200D0 (en
Inventor
Howard L Weiner
Youhai Chen
Original Assignee
Brigham & Womens Hospital
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Brigham & Womens Hospital filed Critical Brigham & Womens Hospital
Publication of NO964200D0 publication Critical patent/NO964200D0/en
Publication of NO964200L publication Critical patent/NO964200L/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4713—Autoimmune diseases, e.g. Insulin-dependent diabetes mellitus, multiple sclerosis, rheumathoid arthritis, systemic lupus erythematosus; Autoantigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/20—Interleukins [IL]
    • A61K38/2026—IL-4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/39—Connective tissue peptides, e.g. collagen, elastin, laminin, fibronectin, vitronectin, cold insoluble globulin [CIG]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0008—Antigens related to auto-immune diseases; Preparations to induce self-tolerance
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/02—Drugs for disorders of the urinary system of urine or of the urinary tract, e.g. urine acidifiers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Rheumatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Pain & Pain Management (AREA)
  • Rehabilitation Therapy (AREA)
  • Toxicology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • Reproductive Health (AREA)
  • Ophthalmology & Optometry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Fremgangsmåte for behandling av autoimmune sykdommer så som multippel sklerose i ved oral administrering av et tilstedeværende antigen så som myelinbasisk protein eller i proteolipid protein sammen med et ikke-interferon polypeptid som har Th2-forsterkende cytokin aktivitet på en slik måte at det induseres oral toleranse overfor tilstedeværende antigene som resulterer i suppressjon av den autoimmune responsen.Method of treating autoimmune diseases such as multiple sclerosis by oral administration of a present antigen such as myelin basic protein or proteolipid protein together with a non-interferon polypeptide having Th2-enhancing cytokine activity in such a way that it induces oral tolerance to antigens present that result in suppression of the autoimmune response.

NO964200A 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines NO964200L (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US22537294A 1994-04-08 1994-04-08
US33252494A 1994-10-31 1994-10-31
PCT/US1995/004512 WO1995027500A1 (en) 1994-04-08 1995-04-07 TREATMENT OF AUTOIMMUNE DISEASE USING ORAL TOLERIZATION AND/OR Th2-ENHANCING CYTOKINES

Publications (2)

Publication Number Publication Date
NO964200D0 NO964200D0 (en) 1996-10-03
NO964200L true NO964200L (en) 1996-10-03

Family

ID=26919544

Family Applications (1)

Application Number Title Priority Date Filing Date
NO964200A NO964200L (en) 1994-04-08 1996-10-03 Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines

Country Status (10)

Country Link
EP (1) EP0752879A4 (en)
JP (1) JPH09511990A (en)
KR (1) KR970702067A (en)
AU (1) AU695883B2 (en)
BR (1) BR9507452A (en)
CA (1) CA2187345A1 (en)
HU (1) HUT76101A (en)
IL (1) IL113301A0 (en)
NO (1) NO964200L (en)
WO (1) WO1995027500A1 (en)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0787147A1 (en) * 1994-10-25 1997-08-06 Immulogic Pharmaceutical Corporation Compositions and treatment for multiple sclerosis
US6841543B1 (en) 1996-01-31 2005-01-11 President And Fellows Of Harvard College Methods of inhibiting production of T helper type 2 cytokines in human immune cells
US5843449A (en) * 1996-03-25 1998-12-01 Akzo Nobel N.V. Proteins and novel peptides derived from autoantigen for use in immunotherapy of autoimmune diseases
US5958671A (en) 1996-04-23 1999-09-28 Presidents And Fellows Of Harvard College Methods and compositions for regulating T cell subsets by modulating transcription factor activity
US6537810B1 (en) 1996-04-23 2003-03-25 President And Fellows Of Harvard College Methods for regulating T cell subsets by modulating transcription factor activity
WO1998006861A2 (en) * 1996-08-15 1998-02-19 Agrivax Incorporated Delivery of tolerogenic antigens via edible plants or plant-derived products
US5939069A (en) * 1996-08-23 1999-08-17 University Of Florida Materials and methods for detection and treatment of immune system dysfunctions
US6211160B1 (en) 1996-09-06 2001-04-03 The Trustees Of The University Of Pennsylvania Method for tolerizing a mammalian patient to administration of gene therapy virus vectors
US6022697A (en) * 1996-11-29 2000-02-08 The Regents Of The University Of California Methods for the diagnosis and treatment of insulin-dependent diabetes mellitus
EP0914163B1 (en) * 1997-02-28 2016-02-24 Enzo Therapeutics, Inc. Processes implementing selective immune down regulation (SIDR)
US20020072493A1 (en) 1998-05-19 2002-06-13 Yeda Research And Development Co. Ltd. Activated T cells, nervous system-specific antigens and their uses
JP2003532618A (en) * 1998-05-19 2003-11-05 イエダ リサーチ アンド デベロプメント カンパニイ リミテッド Cells, nervous system-specific antigens and their uses
AU2001249214A1 (en) 2000-03-15 2001-09-24 The Brigham And Women's Hospital, Inc. Suppression of vascular disorders by mucosal administration of heat shock protein peptides
ES2292594T3 (en) 2000-05-24 2008-03-16 The Government Of The Usa As Represented By The Secretary Of Department Of Health And Human Services E-SELECTINE TO TREAT OR PREVENT CEREBROVASCULAR ACCIDENTS.

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5190750A (en) * 1990-03-09 1993-03-02 Asahi Kasei Kogyo Kabushiki Kaisha Methods for the treatment of demyelinating disease, uveitis, or graft-versus-host disease using tnf
AU9161591A (en) * 1990-12-19 1992-07-22 Schering Corporation Use of il-4 to enhance immune response to immunogens in vaccines
JP3712260B2 (en) * 1992-02-28 2005-11-02 オートイミューン インク Bystander suppression of autoimmune diseases
EP0662837B1 (en) * 1992-10-01 1999-05-19 Schering Corporation Use of il-10 to prevent insulin-dependent diabetes mellitus
DK0603992T4 (en) * 1992-12-22 2001-03-05 Univ Cincinnati Oral administration of immunologically active biomolecules and other therapeutic proteins

Also Published As

Publication number Publication date
JPH09511990A (en) 1997-12-02
KR970702067A (en) 1997-05-13
NO964200D0 (en) 1996-10-03
IL113301A0 (en) 1995-07-31
EP0752879A1 (en) 1997-01-15
HUT76101A (en) 1997-06-30
HU9602751D0 (en) 1996-11-28
WO1995027500A1 (en) 1995-10-19
AU695883B2 (en) 1998-08-27
CA2187345A1 (en) 1995-10-19
EP0752879A4 (en) 1999-07-21
AU2246795A (en) 1995-10-30
BR9507452A (en) 1997-08-05

Similar Documents

Publication Publication Date Title
ATE228373T1 (en) SUPPRESSION OF AUTOIMMUNE DISEASES BY ANTIGENS IN WAITING
NO964200L (en) Treatment of autoimmune disease using oral tolerance and / or Th2-enhancing cytokines
DE68924162D1 (en) STRESS PROTEINS AND USES THEREFOR.
DK0689449T3 (en) Preparations for use in human therapy, characterized by combining a muramyl peptide with a cytokine
ATE287729T1 (en) EPITOPES OF DIPHTHERIATOXIN
EP0663836A1 (en) Treatment of autoimmune and inflammatory disorders.
EP0305967A3 (en) Conjugates of cytokines with immunoglobulins
KR950700333A (en) IMPROVED ALPHA INTERFERON COMPOSITION AND METHOD FOR ITS PRODUCTION FROM HUMAN PERIPHERAL BLOOD LEUKOCYTES
NO931372D0 (en) TREATMENT OF AUTO IMMUNE DISEASES BY ORAL ADMINISTRATION OF AUTO ANTIGENS
NO964199L (en) Treatment of autoimmune disease using oral tolerance and / or type I interferon
EP0726758A4 (en) Peptides for inducing cytotoxic t lymphocyte responses to hepatitis b virus
AU621830B2 (en) Method and dosage form using an antagonist to gamma interferon to control mhc-associated autoimmune disease
DE69519856D1 (en) EXPRESSION OF ALBUMIN IN YEAST
FI843668L (en) HOMOGENT IMMUN-INTERFERONFRAGMENT.
HK1025738A1 (en) Lo-cd2a antibody and uses thereof for inhibiting tcell activation and proliferation
DE69719754D1 (en) THERAPEUTIC USE OF BPI PROTEIN PRODUCTS IN PEOPLE WITH BREEDING THROUGH TRAUMA
DE68928710D1 (en) T cell growth factor
IL113280A0 (en) Method of treating auto-immune diseases using type one interferons
DE69636527D1 (en) ANTIGENE PROTEIN FROM MALASSEZIA
DK0687300T3 (en) LO-CD2a antibody and its uses for inhibiting T cell activation and proliferation
EP0642333A4 (en) Method and composition for the treatment of disorders involving immunological dysfunction.
DK0959899T3 (en) LO-CD2a antibody and its use to inhibit T cell activation and proliferation
RU92008227A (en) METHOD OF IMPROVING MOOD AND ADMINISTRATION
CA2133995A1 (en) Method and composition for the treatment of disorders involving immunological dysfunction

Legal Events

Date Code Title Description
FC2A Withdrawal, rejection or dismissal of laid open patent application